Edition:
United Kingdom

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

4.41USD
19 Jan 2018
Change (% chg)

$-0.10 (-2.22%)
Prev Close
$4.51
Open
$4.53
Day's High
$4.57
Day's Low
$4.29
Volume
4,277
Avg. Vol
10,354
52-wk High
$11.20
52-wk Low
$3.20

Latest Key Developments (Source: Significant Developments)

RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH.RXI PHARMACEUTICALS CORP - COMPANY TO "CAPITALIZE" ON PROPRIETARY SELF-DELIVERING RNAI PLATFORM (SD-RXRNA).RXI PHARMACEUTICALS CORP - 2018 BUSINESS STRATEGY INCLUDES DEVELOPING IMMUNO-ONCOLOGY TARGETS BEYOND CHECKPOINT INHIBITION, I.E. CELL DIFFERENTIATION.RXI PHARMACEUTICALS- RELATING TO OPERATIONAL REVIEW, RXI INTENDS TO PARTNER/OUT-LICENSE BOTH ITS DERMATOLOGY AND OPHTHALMOLOGY FRANCHISES.  Full Article

RXi Pharmaceuticals Announces Reverse Stock Split
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS CORP - ANNOUNCED A REVERSE STOCK SPLIT OF ITS SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-10.RXI PHARMACEUTICALS CORP - REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 12:01 A.M. EASTERN TIME ON JANUARY 8, 2018.RXI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT.  Full Article

RXi Pharma Announces Meets Secondary Objective With RXI-109 For Dermal Scarring
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH RXI-109 FOR DERMAL SCARRING.RXI PHARMACEUTICALS CORP - RXI-109 MEETS SECONDARY OBJECTIVE AS IT WAS SHOWN TO BE SAFE AND WELL TOLERATED.RXI PHARMACEUTICALS CORP -RXI-109 STUDY SUCCESSFULLY MEETS PRIMARY EFFECTIVENESS OBJECTIVE WITH STATISTICALLY SIGNIFICANT OUTCOMES.RXI PHARMACEUTICALS - FULL STUDY RESULTS SHOW RXI-109 WAS SAFE, WELL TOLERATED FOR ALL DOSAGE GROUPS.  Full Article

RXi Pharma and Gustave Roussy have entered into a collaborative research agreement​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Rxi Pharmaceuticals Corp :RXi Pharmaceuticals Corp - ‍co, Gustave Roussy announced that they have entered into a collaborative research agreement​.RXi Pharmaceuticals - ‍collaborative research agreement to evaluate potential of RXi's sd-rxRNA technology platform for use in cancer treatments​.  Full Article

RXi Pharmaceuticals reports Q3 2017 financial results and recent corporate highlights
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - RXi Pharmaceuticals Corp ::Reports third quarter 2017 financial results and recent corporate highlights.At September 30, 2017, company had cash of $5.4 million, compared with $12.9 million at December 31, 2016​.Qtrly loss per share $0.11​.  Full Article

RXi Pharmaceuticals enters into exclusive option agreement to acquire Mirimmune Inc
Wednesday, 12 Oct 2016 

RXi Pharmaceuticals Corp : RXi Pharmaceuticals enters into exclusive option agreement to acquire Mirimmune Inc . RXi Pharmaceuticals Corp - can exercise option to acquire Mirimmune on terms set forth in option agreement at any time prior to April 5, 2017 . RXi Pharmaceuticals Corp - deal for number of shares equal to 19.99% of then outstanding shares of common stock of RXi . RXi Pharmaceuticals Corp - entered into an option agreement to acquire all outstanding capital stock of Mirimmune Inc .RXi Pharmaceuticals Corp - deal also provides for additional potential consideration contingent on Mirimmune reaching certain milestones.  Full Article

RXI Pharmaceuticals Qtrly loss per share $0.34
Thursday, 11 Aug 2016 

RXI Pharmaceuticals Corp : RXI Pharmaceuticals reports second quarter 2016 financial results and highlights recent corporate developments .Net revenue for quarter ended june 30, 2016 was $9,000 as compared with no revenues for quarter ended june 30, 2015.  Full Article

Rxi Pharmaceuticals reports Q1 loss of $0.34 per share
Thursday, 12 May 2016 

Rxi Pharmaceuticals Corp : Qtrly loss per share $0.34 . Believes existing cash, cash equivalents and short-term investments should be sufficient to fund operations for at least one year .Rxi pharmaceuticals reports first quarter 2016 financial results and highlights recent corporate developments.  Full Article

BRIEF-RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

* RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH